Unknown

Dataset Information

0

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.


ABSTRACT: AIMS/HYPOTHESIS:Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic steatosis and fibrosis in patients with type 2 diabetes. METHODS:In this 12 week, parallel, randomised, placebo-controlled trial, performed at the VU University Medical Center between July 2013 and August 2015, 52 overweight patients with type 2 diabetes treated with metformin and/or sulphonylurea agent ([mean ± SD] age 62.7?±?6.9 years, HbA1c 7.3?±?0.7% or 56?±?1 mmol/mol) were allocated to once daily liraglutide 1.8 mg (n?=?17), sitagliptin 100 mg (n?=?18) or matching placebos (n?=?17) by computer generated numbers. Both participants and researchers were blinded to group assignment. Hepatic fat content was measured using proton magnetic resonance spectroscopy (1H-MRS). Hepatic fibrosis was estimated using three validated formulae. RESULTS:One patient dropped out in the sitagliptin group owing to dizziness, but no serious adverse events occurred. At week 12, no between-group differences in hepatic steatosis were found. Liraglutide reduced steatosis by 10% (20.9?±?3.4% to 18.8?±?3.3%), sitagliptin reduced steatosis by 12.1% (23.9?±?3.0% to 21.0?±?2.7%) and placebo lessened it by 9.5% (18.7?±?2.7% to 16.9?±?2.7%). Neither drug affected hepatic fibrosis scores compared with placebo. CONCLUSIONS/INTERPRETATION:Twelve-week liraglutide or sitagliptin treatment does not reduce hepatic steatosis or fibrosis in type 2 diabetes. TRIAL REGISTRATION:ClinicalTrials.gov NCT01744236 FUNDING : Funded by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282521 - the SAFEGUARD project.

SUBMITTER: Smits MM 

PROVIDER: S-EPMC6518065 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

Smits Mark M MM   Tonneijck Lennart L   Muskiet Marcel H A MH   Kramer Mark H H MH   Pouwels Petra J W PJ   Pieters-van den Bos Indra C IC   Hoekstra Trynke T   Diamant Michaela M   van Raalte Daniël H DH   Cahen Djuna L DL  

Diabetologia 20160915 12


<h4>Aims/hypothesis</h4>Glucagon-like peptide (GLP)-1-based therapies have been suggested to improve hepatic steatosis. We assessed the effects of the GLP-1 receptor agonist liraglutide and the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin on hepatic steatosis and fibrosis in patients with type 2 diabetes.<h4>Methods</h4>In this 12 week, parallel, randomised, placebo-controlled trial, performed at the VU University Medical Center between July 2013 and August 2015, 52 overweight patients wit  ...[more]

Similar Datasets

| S-EPMC5129471 | biostudies-literature
| S-EPMC6615254 | biostudies-literature
| S-EPMC6890592 | biostudies-literature
| S-EPMC8134438 | biostudies-literature
| S-EPMC7437086 | biostudies-literature
| S-EPMC5129465 | biostudies-literature
| S-EPMC6635895 | biostudies-literature
| S-EPMC3889333 | biostudies-literature
| S-EPMC5084818 | biostudies-literature
| S-EPMC4374077 | biostudies-literature